A study to assess the outcome in COVID-19 confirmed cases receiving Remdesivir as compared to conventional therapy: Medical records-based audit

Abstract

Introduction: COVID-19 infection caused by SARS-Corona virus-2 (SARS-CoV-2) has caused large number of infections and mortality globally. There are no proven medications to prevent and treat COVID-19, nevertheless several potential pharmacotherapeutic agents have been tried. Remdesivir was found to be effective in few studies. Aims: To assess the outcome in COVID-19 confirmed cases receiving Remdesivir as compared to conventional therapy. Methodology: This study was conducted in a tertiary hospital in South India after the approval of the Institutional ethical committee. It was a medical records-based retrospective, longitudinal study. Medical records of the inpatients with confirmed COVID-19 infection were reviewed from the period of June 15, 2020 to September 15, 2020. This study was conducted to assess the clinical and laboratory profile and outcome in the patients admitted with moderate and severe COVID-19 disease who received Remdesivir. Statistical Analysis: The analysis was done using SPSS Inc. released 2009, PASW statistics for Windows version 18.0, Chicago. Results: One hundred eleven (N = 111) patients were included in the study. 56 patients received the conventional treatment (Hydroxychloroquine HCQ) and 55 patients received Remdesivir. It was seen that among patients treated with HCQ, 24 (42.9%) required non-invasive ventilation and seven (12.7%) patients treated with Remdesivir required it (P = 0.001). It was noticed that the mean duration of hospitalization was 16.6 days in HCQ group and was 11.4 days in Remdesivir group (P = 0.021). Conclusion: The study demonstrates that Remdesivir does have benefit in reducing the mortality and duration of hospital stay. There was reduced requirement of non-invasive and invasive ventilation among patients treated with Remdesivir.

Remdesivir: Effectiveness and Safety in Hospitalized Patients with COVID-19 (ReEs-COVID-19)—Analysis of Data from Daily Practice

“…In most [23][24][25], but not all [26] the observational studies, the 30-day mortality and/or disease progression rates among patients treated with remdesivir for 5 days were higher than those in our study, at around 12-13%. In a recently published Greek study, a 10% mortality rate was reported in three Greek hospitals (4% in 14 days), with a 9-day mean interval between admission and recovery [27].…”

“…In a multicenter international study using data from both an open-label trial and a real-world cohort, the rates of recovery at 14 days since admission were slightly lower (74.4%) compared to those observed in our study (80.9%) [ 22 ]. In most [ 23 , 24 , 25 ], but not all [ 26 ] the observational studies, the 30-day mortality and/or disease progression rates among patients treated with remdesivir for 5 days were higher than those in our study, at around 12–13%. In a recently published Greek study, a 10% mortality rate was reported in three Greek hospitals (4% in 14 days), with a 9-day mean interval between admission and recovery [ 27 ].…”

Remdesivir: Effectiveness and safety in hospitalized patients with COVID-19 (ReEs-COVID19) - Analysis of data from daily practice

“…However, 30-days mortality (3.8%) was lower than that in the ACTT-1 (11%), WHO's Solidarity (15%) and DisCoVeRy (8%) trials (9,12,21). In most (22)(23)(24) but not all (25) observational studies 30-days mortality and/or disease progression rates in patients treated with 5day remdesivir were higher than in our study being around 12-13%. In a recently published Greek study, a 10% mortality rate was reported in three Greek hospitals (4% in 14 days), with a 9-day mean interval between admission and recovery [26].…”